Title:
COMPOUND SUSTAINED-RELEASE TABLET FOR RESISTING HEART FAILURE DISEASES AND PRODUCTION METHOD
Document Type and Number:
WIPO Patent Application WO/2018/192001
Kind Code:
A1
Abstract:
Disclosed are a compound sustained-release tablet for resisting heart failure diseases and a production method therefor. The tablet mainly consists of 20 mg to 40 mg of a tetramethylprazine salt, 2 mg to 10 mg of an angiotensin reductase II inhibitor (ACEI) perindopril salt, 0.4 mg to 1.8 mg of sulfamide diuretic indapamide, 30 mg to 50 mg of pharmaceutical-grade hydroxypropyl methylcellulose K100M, 10 mg to 30 mg of polyvinylpyrrolidone, 60 mg to 100 mg of starch, 0.2 mg to 0.8 mg of magnesium stearate, and 0.2 mg to 0.8 mg of talcum powder.
Inventors:
WANG JIAN (CN)
ZHANG XIN (CN)
YANG RONG (CN)
TANG ZHENG (CN)
HUANG LINGYAN (CN)
ZHANG XIN (CN)
YANG RONG (CN)
TANG ZHENG (CN)
HUANG LINGYAN (CN)
Application Number:
PCT/CN2017/082157
Publication Date:
October 25, 2018
Filing Date:
April 27, 2017
Export Citation:
Assignee:
SHANGHAI PHARMA DONGYING JIANGSU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K9/36; A61K31/404; A61K31/4965; A61K38/05; A61K47/32; A61K47/38; A61P9/04; A61P9/10; A61P9/12
Foreign References:
| CN101658675A | 2010-03-03 |
Other References:
TAI, XIUYANG: "Clinical Observation on Pulmonary Heart Disease Heart Failure in Treating 43 Patients with Tetramethylprazine and Enalapril", JOURNAL OF SHANXI MEDICAL COLLEGE FOR CONTINUING EDUCATION, vol. 20, no. 4, 30 November 2010 (2010-11-30), pages 32 - 33
Download PDF: